Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy
Editorial Group: Cochrane Hepato-Biliary Group
Published Online: 15 APR 2009
Assessed as up-to-date: 23 SEP 2008
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Katz LH, Fraser A, Leibovici L, Tur-Kaspa R. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD005264. DOI: 10.1002/14651858.CD005264.pub2.
- Publication Status: Edited (no change to conclusions)
- Published Online: 15 APR 2009
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the beneficial and harmful effects of lamivudine in preventing reactivation of HBV during or following immunosuppressive therapy in HBsAg-positive patients.
To estimate the optimal time of initiating lamivudine prophylactic therapy in HBsAg-positive patients receiving immunosuppressive therapy.